Double-target-point nerve conduction supporting nutritional composition and preparation method thereof

Abstract

The invention discloses a double-target nerve conduction supporting nutritional composition and a preparation method thereof, and belongs to the technical field of nutritional products. The composition is prepared by compounding DHA algal oil, phosphatidylserine, EGCG and B vitamins with xanthoceras sorbifolia bunge oil nervonic acid and magnesium L-threonate which serve as dual-core targets in parts by mass, a'myelin sheath repair + signal transduction acceleration 'dual-target synergistic system is formed, membrane structure maintenance, oxidation resistance, inflammation resistance and neurotransmitter synthesis support are achieved at the same time, and the composition has the advantages of being simple in preparation process, low in cost and easy to popularize and apply. Neural conduction efficiency is systematically improved and instruction-execution latency is shortened. The problems of non-uniform mixing and caking of liquid oil and powder are solved through microencapsulation, the process is mature, the safety is high, and the stability is good. Animal experiments show that the composition can shorten the time of simple reaction by 30.5% (plt, 0.01) and shorten the time of selective reaction by 29.9% (plt, 0.01), has a non-obvious and unexpected technical effect, and is suitable for long-term nutritional supplement of middle-aged and elderly people and stroke convalescent people.

Description

Technical Field

[0001] This invention belongs to the field of nutritional product technology, specifically relating to a nutritional composition that supports nerve conduction on two targets and its preparation method. Background Technology

[0002] Decreased nerve conduction velocity stems primarily from three factors: myelin degeneration leading to impaired signal skipping transmission, decreased efficiency of signaling proteins such as G protein-coupled receptors causing transduction delays, and oxidative stress and neuroinflammation accelerating nerve aging. Clinically, this manifests as decreased reaction speed, delayed command-execution, and reduced limb coordination, severely impacting the ability to live independently.

[0003] Stroke is a major cause of severe damage to nerve conduction, with 70%-80% of survivors experiencing residual limb motor dysfunction. The core mechanism is damage to nerve conduction pathways such as the corticospinal tract, preventing the efficient transmission of brain commands to muscles. Currently, there is a lack of specific oral nutritional support programs for nerve conduction repair in clinical practice.

[0004] Nervonic acid (C24:1), as a marker structural component of myelin, can upregulate the expression of myelin basic protein MBP, promote nerve fiber repair, and improve limb function after cerebral ischemia. Magnesium L-threonate can cross the blood-brain barrier to increase brain magnesium levels, improve NMDA receptor function and synaptic plasticity, significantly shorten reaction time, and enhance motor coordination.

[0005] Phosphatidylserine (PS) and DHA algal oil have a synergistic effect on membrane structure; DHA provides the structural basis, while PS enhances signal transduction efficiency. EGCG can scavenge free radicals, inhibit neuroinflammation, and protect mitochondria. B vitamins participate in neurotransmitter synthesis and are important cofactors for nerve conduction.

[0006] Xanthoceras sorbifolium oil is liquid, and direct mixing with powdered components can easily lead to unevenness, clumping, and difficulty in filling, necessitating microencapsulation. While existing microencapsulation processes for Xanthoceras sorbifolium oil have been reported, current nervonic acid-related compositions all focus on memory and cognitive improvement, targeting only a single point. No existing technology has disclosed or suggested combining nervonic acid with magnesium L-threonate to form a dual-target synergistic mechanism for improving the specific technical problem of "instruction-execution delay."

[0007] Although existing literature has discussed compound preparations of nervonic acid and magnesium, they all add other active ingredients such as PQQ, NMN, and SOD, which are fundamentally different from the six-component system of this invention, and do not systematically design functions for nerve conduction efficiency and instruction-execution delay.

[0008] Therefore, existing technologies lack a nutritional composition that offers dual-target synergy, multi-dimensional support, and can significantly improve nerve conduction velocity, making the development of such products of significant practical importance. Summary of the Invention

[0009] To address the shortcomings of existing technologies, such as single-target nutritional compositions, lack of dual-target systemic neural conduction support, and difficulties in liquid-solid raw material mixing processes, this invention provides a nutritional composition with dual-target synergy that can significantly improve instruction-execution delay; at the same time, it provides a stable preparation method suitable for industrial production.

[0010] This application provides a nutritional composition that supports nerve conduction on two targets, comprising, by weight: Sapindus mukorossi oil (containing nervonic acid) 200-600 parts 100-400 parts of L-threonate magnesium 50-200 parts of DHA algal oil Phosphatidylserine 20-150 parts EGCG 20-100 doses 10-80 parts of a vitamin B complex mixture The mass ratio of vitamin B1, vitamin B6 and vitamin B12 is (5-15):(5-15):(0.01-0.1).

[0011] The mass fractions described in this invention refer to the mass ratio between the active ingredients, and do not include excipients such as microcapsule wall materials. The amount of materials added can be increased or decreased proportionally during production.

[0012] Preferably, the nervonic acid content in the *Sapindus mukorossi* oil is ≥2%; the DHA content in the DHA algal oil is ≥20%; and the purity of the phosphatidylserine is ≥50%.

[0013] More preferably, based on parts by mass, the amounts of each component are as follows: 300-500 parts of Sapindus mukorossi oil 150-300 parts of L-threonate magnesium 80-150 parts DHA algal oil Phosphatidylserine 40-100 parts EGCG 30-80 doses 20-60 parts of a vitamin B complex mixture Most preferably, based on parts by mass, the amounts of each component are as follows: 400 portions of Sapindus mukorossi oil 200 parts of L-magnesium threonate 100 parts DHA algal oil 50 parts of phosphatidylserine 50 servings of EGCG 30 parts of a vitamin B complex mixture (15 parts vitamin B1, 14.9 parts vitamin B6, and 0.1 part vitamin B12) The present invention also provides a method for preparing the above-mentioned dual-target neurotrophic composition, comprising the following steps: (1) Microencapsulation of Xanthoceras sorbifolium oil: The wall material gelatin and sucrose were dissolved in water at a mass ratio of 1:5, with a solid content of 20%; Xanthoceras sorbifolium oil was slowly added to the wall material solution under stirring conditions, with a core material loading of 35%; the mixture was dispersed for 5 to 10 minutes at 10,000 to 15,000 rpm using a high-speed disperser, and then homogenized 2 to 3 times at 20 to 40 MPa pressure using a high-pressure homogenizer; the resulting emulsion was spray-dried at an inlet air temperature of 170 to 180°C and an outlet air temperature of 75 to 85°C to obtain Xanthoceras sorbifolium oil microcapsule powder; (2) Pretreatment of other components: The mixture of L-threonate magnesium, EGCG and vitamin B complex was microencapsulated using modified starch as the wall material; DHA algal oil and phosphatidylserine were microencapsulated using commercially available powders. (3) Total mixing: The *Sapindus mukorossi* oil microcapsule powder obtained in step (1) and the pretreated component powders in step (2) are placed in a three-dimensional motion mixer and mixed at a speed of 15-20 rpm for 20-30 minutes. The mixing environment temperature is ≤25℃ and the relative humidity is ≤45% to obtain a uniform total mixed powder. (4) Filling: Fill the total mixed powder obtained in step (3) into plant hydroxypropyl methylcellulose (HPMC) hard capsules, with each capsule containing 400-800 mg of contents.

[0014] The essential features of this invention are as follows: For the first time, a dual-target core mechanism of "myelin repair + signal transduction acceleration" was constructed, and the nervonic acid of Sapindus mukorossi oil and magnesium L-threonate were precisely combined. There is no inspiration for this combination in existing technologies. A six-component specific compound system is formed to achieve a five-in-one synergistic effect of dual-target core + membrane function maintenance + antioxidant and anti-inflammatory + neurotransmitter synthesis; The composition is specifically applied to improve instruction-execution latency, which is different from traditional memory improvement products and represents a new application direction. Microencapsulation solves the problem of uneven liquid-solid mixing, achieving uniform filling and consistent content.

[0015] The significant advancement of this invention lies in: Through synergistic effects of specific formulations, the simple reaction time was reduced by 30.5%, and the selected reaction time was reduced by 29.9%, with statistically significant differences (p<0.01). The absence of any core component significantly reduced the effect, proving that the effect is not a simple additive effect of the individual components, but has unexpected technical effects.

[0016] The dual-target core synergy has effects that are not simply additive, but have unexpected technological benefits: nervonic acid is used to repair myelin sheath structure, and magnesium L-threonate is used to accelerate ion channel signal transduction, forming a dual-target core support; combined with DHA+PS membrane stabilization, EGCG antioxidant and anti-inflammatory effects, and B vitamin neurotransmitter synthesis support, the five mechanisms work synergistically to achieve systemic support for nerve conduction.

[0017] Significantly improves instruction-execution delay with remarkable effect: Animal experiments showed that the simple reaction time of Example 1 was shortened by 30.5% and the selected reaction time was shortened by 29.9% (p<0.01); the effects of Comparative Example 1 (magnesium deficiency) and Comparative Example 2 (nervonic acid deficiency) were significantly reduced, proving that the two core components are indispensable and have a prominent synergistic effect.

[0018] Solving the challenges of liquid-solid mixing: Microencapsulation transforms Xanthoceras sorbifolium oil into a free-flowing powder with an encapsulation rate of ≥85% and a surface oil content of ≤5%, achieving uniform mixing and making it suitable for capsule filling and industrial production.

[0019] High safety profile, suitable for long-term use: The dosage of each component is within the international safety limit, and toxicological tests show no genotoxicity or subchronic toxicity, making it suitable for long-term nutritional supplementation for middle-aged and elderly people and those in the recovery period after stroke.

[0020] Excellent stability and controllable quality: After 3 months of accelerated stability, the effective ingredient retention rate is ≥90%, and the microbial content complies with GB16740-2014, ensuring stable and controllable product quality. Attached Figure Description

[0021] Figure 1 The flowchart of the preparation process of the nutritional composition that supports nerve conduction on dual targets in this invention.

[0022] Figure 2 Example 1: Scanning electron microscope image of Xanthoceras sorbifolium oil microcapsule powder (×5000).

[0023] Figure 3 Example 1: Schematic diagram of the appearance of the finished hard capsule. Detailed Implementation

[0024] To facilitate understanding of this application, a more complete description will be provided below with reference to the accompanying drawings. Preferred embodiments of this application are shown in the drawings. However, this application can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a more thorough and complete understanding of the disclosure of this application.

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The terms “and / or” and “and / or” as used herein include any and all combinations of one or more of the associated listed items.

[0026] The application will be further described below with reference to the accompanying drawings and embodiments.

[0027] See Figures 1 to 3 As shown, Figure 1 This is a flowchart illustrating the preparation process of the nutritional composition for dual-target nerve conduction support of the present invention.

[0028] Example 1 The raw material proportions (based on effective core material) are as follows, by weight: Sapindus mukorossi oil (nervonic acid ≥2%): 400 parts L-Magnesium Threonate: 200 parts DHA algal oil (DHA≥20%): 100 parts Phosphatidylserine (purity ≥50%): 50 parts EGCG: 50 copies Vitamin B complex mixture: 30 servings Of which: Vitamin B1 15 parts, Vitamin B6 14.9 parts, Vitamin B12 0.1 parts Each capsule contains a total of 830mg of active ingredients.

[0029] Preparation method: (1) Microencapsulation of Xanthoceras sorbifolium oil: The wall material gelatin and sucrose were dissolved in water at a mass ratio of 1:5, and the solid content was adjusted to 20%. Under stirring conditions, 400 parts by weight of Xanthoceras sorbifolium oil were slowly added to the wall material solution, with a core material loading of 35%. The mixture was dispersed for 8 minutes at 12000 rpm using a high-speed disperser, and then homogenized three times under a high-pressure homogenizer at 30 MPa. The resulting emulsion was spray-dried at an inlet air temperature of 175℃, an outlet air temperature of 80℃, and a feed flow rate of 650 mL / h to obtain Xanthoceras sorbifolium oil microcapsule powder. The encapsulation rate was 87.3%, the surface oil content was 3.8%, the moisture content was 2.49%, and the particle size distribution was in the range of 10–50 μm. The product was a free-flowing, pale yellow powder with no odor.

[0030] (2) Pretreatment of other components: The mixture of L-threonate magnesium, EGCG and vitamin B complex was microencapsulated using modified starch as the wall material. DHA algal oil and phosphatidylserine were microencapsulated using commercially available powders.

[0031] (3) Total mixing: The *Sapindus mukorossi* oil microcapsule powder obtained in step (1) and the pretreated component powders in step (2) are placed in a three-dimensional motion mixer and mixed at 18 rpm for 25 minutes. The temperature is controlled at ≤25℃ and the relative humidity is ≤45% to obtain a uniform total mixed powder.

[0032] (4) Filling: Fill the total mixed powder obtained in step (3) into plant HPMC hard capsules, with each capsule containing 830mg ± 5% of the contents.

[0033] Example 2 The raw material proportions are as follows, by weight: Sapindus mukorossi oil (nervonic acid ≥2%): 300 parts L-Magnesium Threonate: 300 parts DHA algal oil (DHA ≥ 20%): 150 parts Phosphatidylserine (purity ≥50%): 80 parts EGCG: 80 copies Vitamin B complex mixture: 50 servings The mass ratio of vitamin B1, B6, and B12 in the vitamin B complex mixture is 10:10:0.05.

[0034] The preparation method is the same as in Example 1.

[0035] Example 3 The raw material proportions are as follows, by weight: Sapindus mukorossi oil (nervonic acid ≥2%): 500 parts L-Magnesium threonate: 150 parts DHA algal oil (DHA ≥ 20%): 80 parts Phosphatidylserine (purity ≥50%): 40 parts EGCG: 40 doses Vitamin B complex mixture: 20 servings The mass ratio of vitamins B1, B6, and B12 in the vitamin B complex mixture is 8:8:0.04.

[0036] The preparation method is the same as in Example 1.

[0037] Comparative Example 1 The difference between this comparative example and Example 1 is that L-threonate magnesium is not added, while the other components and proportions are the same as in Example 1.

[0038] Comparative Example 2 The difference between this comparative example and Example 1 is that no *Sapindus mukorossi* oil was added, while the other ingredients and proportions are the same as in Example 1.

[0039] Comparative Example 3 The difference between this comparative example and Example 1 is that EGCG is not added, while the other ingredients and proportions are the same as in Example 1.

[0040] Effect verification test Test Method Description Simple reaction time: Using an audio-visual stimulus reaction timer, the time from the appearance of the stimulus to the button response is recorded (unit: milliseconds).

[0041] When selecting a response time: a multi-target recognition task is used to measure the delay time (in milliseconds) for correctly identifying and executing an action.

[0042] Experiment 1: Evaluation of the microencapsulation effect of Xanthoceras sorbifolium oil The *Sapindus mukorossi* oil microcapsule powder was prepared according to step (1) of Example 1, and its key quality indicators were determined. The results showed that the encapsulation rate was 87.3%, the surface oil content was 3.8%, the moisture content was 2.49%, the particle size distribution was in the range of 10–50 μm, the product had good sensory quality, and excellent solubility and storage stability.

[0043] Experiment 2: Effects of the composition on nerve conduction function (animal experiment) The compositions prepared in Examples 1-3 and Comparative Examples 1-3 were filled into hard capsules and fed to SD rats at a dose of 2 capsules daily (equivalent to the adult recommended dose based on the active ingredient) for 8 consecutive weeks, with 10 rats in each group. At the end of the 8th week, the simple reaction time and selected reaction time were measured using a reaction time test device. The results are shown in the table below: Note: Compared with the blank control group, p<0.05, p<0.01.

[0044] The results showed that, compared with Comparative Example 1 (without L-threonate magnesium) and Comparative Example 2 (without Xanthoceras sorbifolium oil), the test animals in Examples 1-3 exhibited significantly shorter reaction times in the reaction time test (p<0.05 or p<0.01), indicating that the synergistic effect of the components in the composition of the present invention has a significant effect on supporting nerve conduction function. Among them, Example 1 showed the most significant effect, with a 30.5% reduction in simple reaction time and a 29.9% reduction in selected reaction time.

[0045] Experiment 3: Stability Study of the Composition The composition obtained in Example 1 was subjected to accelerated stability testing at 40°C and 75% relative humidity. Samples were taken at 0, 1, 2, and 3 months to detect the contents of nervonic acid, magnesium ions, DHA, PS, EGCG, and B vitamins. The results showed that the contents of each component remained above 90% of the labeled amount within 3 months, indicating that the composition of the present invention has good stability.

[0046] After 3 months of accelerated testing, the capsules showed no sticking or discoloration, and the microbial limits (bacteria, mold, yeast) met the requirements of the national standard GB 16740-2014, indicating that the product met the quality standards.

[0047] Beneficial effects This application is the first to construct a dual-target core mechanism of "myelin repair + signal transduction acceleration", precisely combining nervonic acid from Xanthoceras sorbifolium oil with magnesium L-threonate, a combination not found in existing technologies; forming a six-component specific compound system, achieving a five-in-one synergistic effect of dual-target core + membrane function maintenance + antioxidant and anti-inflammatory + neurotransmitter synthesis; the composition is targeted to improve instruction-execution delay, which is different from traditional memory improvement products and belongs to a new application direction; the problem of uneven liquid-solid mixing is solved by microencapsulation, achieving uniform filling and content uniformity.

[0048] Furthermore, through synergistic effects of specific formulations, the simple reaction time was reduced by 30.5%, and the selected reaction time was reduced by 29.9%, with statistically significant differences (p<0.01). The absence of any core component significantly reduced the effect, proving that the effect is not a simple additive effect of the individual components, but has unexpected technical effects.

[0049] Furthermore, the dual-target core synergy has effects that are not simply additive, but have unexpected technological benefits: nervonic acid is used to repair myelin sheath structure, and magnesium L-threonate is used to accelerate ion channel signal transduction, forming a dual-target core support; combined with DHA+PS membrane stabilization, EGCG antioxidant and anti-inflammatory effects, and B vitamin neurotransmitter synthesis support, the five mechanisms work synergistically to achieve systemic support for nerve conduction.

[0050] Significantly improves instruction-execution delay with remarkable effect: Animal experiments showed that the simple reaction time of Example 1 was shortened by 30.5% and the selected reaction time was shortened by 29.9% (p<0.01); the effects of Comparative Example 1 (magnesium deficiency) and Comparative Example 2 (nervonic acid deficiency) were significantly reduced, proving that the two core components are indispensable and have a prominent synergistic effect.

[0051] Solving the challenges of liquid-solid mixing: Microencapsulation transforms Xanthoceras sorbifolium oil into a free-flowing powder with an encapsulation rate of ≥85% and a surface oil content of ≤5%, achieving uniform mixing and making it suitable for capsule filling and industrial production.

[0052] High safety profile, suitable for long-term use: The dosage of each component is within the international safety limit, and toxicological tests show no genotoxicity or subchronic toxicity, making it suitable for long-term nutritional supplementation for middle-aged and elderly people and those in the recovery period after stroke.

[0053] Excellent stability and controllable quality: After 3 months of accelerated stability, the effective ingredient retention rate is ≥90%, and the microbial content complies with GB16740-2014, ensuring stable and controllable product quality.

[0054] Application Scenario Description The composition of this invention can be used for nutritional support in individuals experiencing limb motor dysfunction after stroke (including ischemic and hemorrhagic stroke). The core pathological manifestation in this population is "command-execution delay" caused by damage to neural conduction pathways (especially the corticospinal tract)—the brain issues commands, but the limbs cannot execute them as intended. The composition of this invention provides nutritional support through the following mechanisms: nervonic acid promotes myelin repair; magnesium L-threonate supports the efficiency of G protein signaling pathways; DHA and PS maintain the structure and function of nerve cell membranes; EGCG reduces oxidative stress damage; and B vitamins assist in neurotransmitter synthesis. These components work synergistically to provide the necessary nutritional foundation for the repair of the damaged neural conduction system, helping to improve the synchronization between limb movements and brain commands. This product is a nutritional support program and can be used as an adjunct nutritional supplement for clinical and home rehabilitation.

[0055] Safety and target audience Suitable for: middle-aged and elderly people, those with declining nerve conduction function, those prone to brain fatigue and slow reaction; and people in the rehabilitation period who have limb motor dysfunction after stroke (including ischemic and hemorrhagic stroke).

[0056] Not suitable for: pregnant women, breastfeeding women, patients with epilepsy, and those taking anticoagulants; contraindicated for infants and young children.

[0057] Recommended daily dosage: 1-2 capsules daily, taken with warm water, preferably with meals.

[0058] Dosage justification: The daily intake of nervonic acid and magnesium ions in this formula is ≤200mg and ≤200mg. All components are within the tolerable daily intake range recommended by the National Center for Food Safety Risk Assessment. Long-term use will not cause significant burden on the liver and kidneys.

[0059] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0060] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. A nutritional composition that supports nerve conduction on two targets, characterized in that, The product comprises, by weight, 200-600 parts of *Sapindus mukorossi* oil (containing nervonic acid), 100-400 parts of magnesium L-threonate, 50-200 parts of DHA algal oil, 20-150 parts of phosphatidylserine, 20-100 parts of EGCG, and 10-80 parts of a mixture of B vitamins.

2. The nutritional composition according to claim 1, characterized in that, The vitamin B complex mixture comprises vitamin B1, vitamin B6 and vitamin B12 in a mass ratio of (5-15):(5-15):(0.01-0.1).

3. The nutritional composition according to claim 1, characterized in that, The nervonic acid content in the *Sapindus mukorossi* oil is ≥2%.

4. The nutritional composition according to claim 1, characterized in that, The DHA algal oil contains ≥20% DHA.

5. The nutritional composition according to claim 1, characterized in that, The purity of the phosphatidylserine is ≥50%.

6. The nutritional composition according to claim 1, characterized in that, The amounts of each component by weight are as follows: 400 parts of Xanthoceras sorbifolium oil, 200 parts of magnesium L-threonate, 100 parts of DHA algal oil, 50 parts of phosphatidylserine, 50 parts of EGCG, and 30 parts of a mixture of B vitamins.

7. A method for preparing a nutritional composition for supporting nerve conduction with dual targets as described in any one of claims 1 to 6, characterized in that, Includes the following steps: (1) The oil of *Sapindus mukorossi* was spray-dried and microencapsulated to form microcapsule powder; (2) The mixture of L-threonate magnesium, EGCG and vitamin B complex was microencapsulated, and DHA algal oil and phosphatidylserine were microencapsulated powders. (3) Mix all the powders evenly; (4) Fill into hard capsules.

8. The preparation method according to claim 7, characterized in that, The process of step (1) is as follows: wall material gelatin: sucrose = 1:5, solid content 20%, core material loading 35%; disperse at 10000~15000rpm for 5~10min, homogenize at 20~40MPa 2~3 times; spray dry with inlet air temperature of 170~180℃ and outlet air temperature of 75~85℃.

9. The preparation method according to claim 7, characterized in that, Step (3) Use a three-dimensional motion mixer to mix at 15-20 rpm for 20-30 min, with an ambient temperature ≤25℃ and relative humidity ≤45%.

10. The preparation method according to claim 7, characterized in that, Step (4) uses HPMC plant capsules, each containing 400-800 mg of contents.

Images